ZUNVEYL benzgalantamine

Drug Class

Acetylcholinesterase inhibitor (AChEI)

Mechanism

Benzgalantamine is a pharmacologically inactive prodrug of galantamine that is metabolized into active galantamine, which competitively inhibits acetylcholinesterase and allosterically modulates nicotinic acetylcholine receptors.

Approved Indication

Treatment of mild to moderate dementia of the Alzheimer’s type in adults.

What This Means For Patients

ZUNVEYL is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2024) — Sources

Pivotal Clinical Evidence

No peer-reviewed pivotal trial on file yet.

Sources

• https://www.alphacognition.com/
• https://www.fda.gov/
• https://doi.org/10.1002/alz70859_107147